Correlation Between Moleculin Biotech and Kymera Therapeutics

Can any of the company-specific risk be diversified away by investing in both Moleculin Biotech and Kymera Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Moleculin Biotech and Kymera Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Moleculin Biotech and Kymera Therapeutics, you can compare the effects of market volatilities on Moleculin Biotech and Kymera Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Moleculin Biotech with a short position of Kymera Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Moleculin Biotech and Kymera Therapeutics.

Diversification Opportunities for Moleculin Biotech and Kymera Therapeutics

0.75

Correlation Coefficient

Moleculin Biotech  Kymera Therapeutics

Poor diversification

The 3 months correlation between Moleculin and Kymera is 0.75. Overlapping area represents the amount of risk that can be diversified away by holding Moleculin Biotech and Kymera Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kymera Therapeutics and Moleculin Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Moleculin Biotech are associated (or correlated) with Kymera Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kymera Therapeutics has no effect on the direction of Moleculin Biotech i.e., Moleculin Biotech and Kymera Therapeutics go up and down completely randomly.

Pair Corralation between Moleculin Biotech and Kymera Therapeutics

Given the investment horizon of 90 days Moleculin Biotech is expected to generate 1.32 times more return on investment than Kymera Therapeutics. However, Moleculin Biotech is 1.32 times more volatile than Kymera Therapeutics. It trades about 0.11 of its potential returns per unit of risk. Kymera Therapeutics is currently generating about 0.01 per unit of risk. If you would invest  173.00  in Moleculin Biotech on October 22, 2024 and sell it today you would earn a total of  15.00  from holding Moleculin Biotech or generate 8.67% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Moleculin Biotech  vs.  Kymera Therapeutics

Moleculin Biotech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Moleculin Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Kymera Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Kymera Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Moleculin Biotech and Kymera Therapeutics

The main advantage of trading using opposite Moleculin Biotech and Kymera Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Moleculin Biotech position performs unexpectedly, Kymera Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will offset losses from the drop in Kymera Therapeutics' long position.

The idea behind Moleculin Biotech and Kymera Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.